BVXP Stock Overview
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Bioventix PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£32.00 |
| 52 Week High | UK£51.00 |
| 52 Week Low | UK£29.77 |
| Beta | 0.42 |
| 1 Month Change | 0.79% |
| 3 Month Change | -12.33% |
| 1 Year Change | -27.68% |
| 3 Year Change | 0.47% |
| 5 Year Change | -15.79% |
| Change since IPO | 1,541.03% |
Recent News & Updates
Estimating The Fair Value Of Bioventix PLC (LON:BVXP)
Jun 19
Bioventix's (LON:BVXP) Dividend Will Be £0.68
Mar 29Recent updates
Estimating The Fair Value Of Bioventix PLC (LON:BVXP)
Jun 19Bioventix's (LON:BVXP) Dividend Will Be £0.68
Mar 29We Think Shareholders May Consider Being More Generous With Bioventix PLC's (LON:BVXP) CEO Compensation Package
Dec 01Bioventix (LON:BVXP) Is Increasing Its Dividend To £0.62
Mar 30Bioventix (LON:BVXP) Is Increasing Its Dividend To UK£0.52
Mar 31Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?
Mar 29Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?
Mar 14What Does Bioventix's (LON:BVXP) CEO Pay Reveal?
Feb 27Shareholders of Bioventix (LON:BVXP) Must Be Delighted With Their 364% Total Return
Jan 31Is Bioventix PLC (LON:BVXP) Popular Amongst Insiders?
Jan 18
Is Bioventix PLC's (LON:BVXP) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 06Here's How We Evaluate Bioventix PLC's (LON:BVXP) Dividend
Dec 23Does Bioventix's (LON:BVXP) CEO Salary Compare Well With Industry Peers?
Nov 28Shareholder Returns
| BVXP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.9% | 0.1% |
| 1Y | -27.7% | -20.2% | 9.0% |
Return vs Industry: BVXP underperformed the UK Biotechs industry which returned -20.2% over the past year.
Return vs Market: BVXP underperformed the UK Market which returned 9% over the past year.
Price Volatility
| BVXP volatility | |
|---|---|
| BVXP Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BVXP has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: BVXP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 17 | Peter Harrison | www.bioventix.com |
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. It also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results.
Bioventix PLC Fundamentals Summary
| BVXP fundamental statistics | |
|---|---|
| Market cap | UK£167.03m |
| Earnings (TTM) | UK£8.10m |
| Revenue (TTM) | UK£13.61m |
20.6x
P/E Ratio12.3x
P/S RatioIs BVXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVXP income statement (TTM) | |
|---|---|
| Revenue | UK£13.61m |
| Cost of Revenue | UK£925.53k |
| Gross Profit | UK£12.68m |
| Other Expenses | UK£4.58m |
| Earnings | UK£8.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.55 |
| Gross Margin | 93.20% |
| Net Profit Margin | 59.51% |
| Debt/Equity Ratio | 0% |
How did BVXP perform over the long term?
See historical performance and comparisonDividends
4.8%
Current Dividend Yield100%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 21:16 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioventix PLC is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Buxton | Cavendish |
| null null | Cavendish |
| Adam McCarter | Cavendish |